Finshots Daily

The downfall of 23andMe?

13 snips
Feb 6, 2024
Explore the downfall of 23andMe, a once high-valued health tech company, due to their inconsistent business model and flawed health predictions. Discuss the risks of false positives in genetic testing, data security concerns, and challenges of becoming a drug maker. Uncertainty surrounds the company's future.
Ask episode
Chapters
Transcript
Episode notes
1
Introduction
00:00 • 2min
2
The Downfall of 23andMe: An Inconsistent Business Model and Problematic Health Predictions
02:01 • 2min
3
The Potential Downfall of 23andMe: False Positives, Data Security, and Drug-Making Ambitions
04:26 • 4min